CompletedNot Applicable

EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy

United States150 participantsStarted 2016-03-18

Plain-language summary

This clinical trial studies how well endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) after positron emission tomography/computed tomography (PET/CT) scan works in diagnosing patients with stage I-IIA non-small cell lung cancer evaluated for stereotactic body radiation therapy (SBRT). Performing EBUS-TBNA after PET/CT scan may help doctors learn more about the accuracy and ways to find early stage lung cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patient must be \> 18 years old
✓. Patient must have proven or suspected non small cell lung cancer (NSCLC) and be clinical Stage I or IIa, according to the 7th edition staging system of the American Joint Commission on Cancer for lung cancer (T1 or T2a, N0 or N1, M0)
✓. Patient must have a PET/CT obtained within 40 days of having the EBUS-TBNA
✓. Patient is being considered for SBRT
✓. Patient or the patient's legally authorized representative must provide written informed consent prior to registration and any study-related procedures
✓. If the patient is a survivor of a prior invasive cancer, all of the following criteria must apply: a) Patient has undergone potentially curative therapy for all prior malignancies b) No evidence of active / recurrent disease within 5 years

Exclusion criteria

✕. Patient has received prior chemotherapy or radiotherapy for this cancer
✕. Patients already scheduled to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression)
✕. Patients malignancy is consistent with well differentiated neuroendocrine (carcinoid) histology
✕. Patients who are planning to undergo treatment in a different institution

What they're measuring

Lymphnode Staging Accuracy

Timeframe: 1 day

Trial details

NCT IDNCT02719847

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-12

View on ClinicalTrials.gov More Lung Cancer trials